Characteristics of cohort
| Characteristic . | Patients, n (%) . | PY* . | |
|---|---|---|---|
| Total . | Mean (SD) . | ||
| Total | 8164 (100) | 49058 | 6.0 (5.1) |
| Sex | |||
| Male | 4827 (59) | 28938 | 6.0 (5.1) |
| Female | 3337 (41) | 20120 | 6.0 (5.2) |
| Race (self-reported) | |||
| White | 7214 (88) | 44414 | 6.2 (5.2) |
| Nonwhite | 950 (12) | 4644 | 4.9 (4.4) |
| Country of birth | |||
| Australia or New Zealand | 5727 (70) | 35876 | 6.3 (5.1) |
| Europe | 1015 (12) | 6561 | 6.5 (5.1) |
| Asia | 431 (5) | 2387 | 5.5 (4.6) |
| Other or unknown | 991 (12) | 4234 | 4.3 (4.9) |
| Cause of primary renal disease | |||
| Diabetic nephropathy | 801 (10) | 4177 | 5.2 (4.6) |
| Primary or secondary glomerulonephritis | 2931 (36) | 17259 | 5.9 (5.2) |
| Hypertensive or arteriopathic | 484 (6) | 2754 | 5.7 (5.0) |
| All other and unknown causes | 3948 (48) | 24868 | 6.3 (5.2) |
| Age at first transplantation | |||
| Younger than 20 y | 710 (8.7) | 4572 | 6.4 (5.4) |
| 20-50 y | 4639 (56.8) | 29477 | 6.4 (5.3) |
| 50-70 y | 2784 (34.1) | 14925 | 5.4 (4.6) |
| 70 y or older | 31 (0.4) | 84 | 2.7 (2.9) |
| Source of first transplant | |||
| Living related donor | 1694 (21) | 9068 | 5.4 (4.6) |
| Cadaver or living unrelated donor | 6470 (79) | 39990 | 6.2 (5.2) |
| Calendar year at first transplantation | |||
| Before 1985 | 930 (11) | 7162 | 7.8 (7.5) |
| 1985-1995 | 4084 (50) | 32322 | 7.9 (4.9) |
| 1996 or later | 3150 (39) | 9475 | 3.0 (2.1) |
| EBV IgG serostatus at transplantation | |||
| Positive | 2668 (33) | 9941 | 3.7 (3.0) |
| Unknown | 4605 (56) | 34860 | 7.6 (5.7) |
| Negative | 891 (11) | 4258 | 4.8 (3.8) |
| Selected immunosuppression regimen†‡ | |||
| CNI + Aza/MMF | 6320 (81) | 30960 | 4.9 (4.2) |
| CNI, no Aza/MMF | 2101 (27) | 6545 | 3.1 (4.0) |
| Aza/MMF, no CNI | 1726 (22) | 10140 | 5.9 (6.8) |
| Other combination | 160 (2) | 147 | 0.9 (1.4) |
| Received T cell–depleting antibodies† | |||
| No | 6664 (94) | 38072 | 5.0 (5.1) |
| Yes§ | 1829 (22) | 10986 | 6.0 (5.4) |
| Monoclonal (monomurab-CD3) | 1083 (59) | 6208 | 5.7 (5.1) |
| Polyclonal (ATG/ALG) | 880 (48) | 5501 | 6.3 (6.2) |
| Characteristic . | Patients, n (%) . | PY* . | |
|---|---|---|---|
| Total . | Mean (SD) . | ||
| Total | 8164 (100) | 49058 | 6.0 (5.1) |
| Sex | |||
| Male | 4827 (59) | 28938 | 6.0 (5.1) |
| Female | 3337 (41) | 20120 | 6.0 (5.2) |
| Race (self-reported) | |||
| White | 7214 (88) | 44414 | 6.2 (5.2) |
| Nonwhite | 950 (12) | 4644 | 4.9 (4.4) |
| Country of birth | |||
| Australia or New Zealand | 5727 (70) | 35876 | 6.3 (5.1) |
| Europe | 1015 (12) | 6561 | 6.5 (5.1) |
| Asia | 431 (5) | 2387 | 5.5 (4.6) |
| Other or unknown | 991 (12) | 4234 | 4.3 (4.9) |
| Cause of primary renal disease | |||
| Diabetic nephropathy | 801 (10) | 4177 | 5.2 (4.6) |
| Primary or secondary glomerulonephritis | 2931 (36) | 17259 | 5.9 (5.2) |
| Hypertensive or arteriopathic | 484 (6) | 2754 | 5.7 (5.0) |
| All other and unknown causes | 3948 (48) | 24868 | 6.3 (5.2) |
| Age at first transplantation | |||
| Younger than 20 y | 710 (8.7) | 4572 | 6.4 (5.4) |
| 20-50 y | 4639 (56.8) | 29477 | 6.4 (5.3) |
| 50-70 y | 2784 (34.1) | 14925 | 5.4 (4.6) |
| 70 y or older | 31 (0.4) | 84 | 2.7 (2.9) |
| Source of first transplant | |||
| Living related donor | 1694 (21) | 9068 | 5.4 (4.6) |
| Cadaver or living unrelated donor | 6470 (79) | 39990 | 6.2 (5.2) |
| Calendar year at first transplantation | |||
| Before 1985 | 930 (11) | 7162 | 7.8 (7.5) |
| 1985-1995 | 4084 (50) | 32322 | 7.9 (4.9) |
| 1996 or later | 3150 (39) | 9475 | 3.0 (2.1) |
| EBV IgG serostatus at transplantation | |||
| Positive | 2668 (33) | 9941 | 3.7 (3.0) |
| Unknown | 4605 (56) | 34860 | 7.6 (5.7) |
| Negative | 891 (11) | 4258 | 4.8 (3.8) |
| Selected immunosuppression regimen†‡ | |||
| CNI + Aza/MMF | 6320 (81) | 30960 | 4.9 (4.2) |
| CNI, no Aza/MMF | 2101 (27) | 6545 | 3.1 (4.0) |
| Aza/MMF, no CNI | 1726 (22) | 10140 | 5.9 (6.8) |
| Other combination | 160 (2) | 147 | 0.9 (1.4) |
| Received T cell–depleting antibodies† | |||
| No | 6664 (94) | 38072 | 5.0 (5.1) |
| Yes§ | 1829 (22) | 10986 | 6.0 (5.4) |
| Monoclonal (monomurab-CD3) | 1083 (59) | 6208 | 5.7 (5.1) |
| Polyclonal (ATG/ALG) | 880 (48) | 5501 | 6.3 (6.2) |
PY indicates person-years; CNI, calcineurin inhibitor; Aza, azathioprine; MMF, mycophenolate; ATG, antithymocyte globulin; and ALG, antilymphocyte globulin.
PYs during first functioning transplantation.
Time-dependent; antibodies Yes from first receipt.
Excludes 335 patients with incomplete drug history.
Patients (n = 134) received both agents; total exceeds 100%.